OBJECTIVE:To probe into the clinical characteristics of camrelizumab-related immune myocarditis,so as to provide reference for clinical rational medication.METHODS:CNKI,Wanfang Data,VIP,PubMed,Embase,Wiley Online Library were retrieved(the retrieval time was from the establishment of the database to Oct.2023),case reports on camrelizumab-related immune myocarditis were collected and analyzed.RESULTS:A total of 22 case reports on camrelizumab-related immune myocarditis were enrolled,including 23 patients,of which 13(56.52％)were males and 10(43.48％)were females;the average age was 64.61 years;the main clinical diagnoses were lung cancer(7 cases,30.43％)and liver cancer(5 cases,21.74％);the median time of the occurrence of immune myocarditis was 23 d after the first medication.The most common clinical symptoms were weakness(9 cases),blepharoptosis(7 cases),chest distress(7 cases),and muscle soreness or weakness(6 cases).All the patients were treated with glucocorticosteroids or in combination with other treatments,and 18 cases got better,4 cases died,1 case had secondary heart failure and left hospital without cure after shock.CONCLUSIONS:Camrelizumab causes low incidence and high lethality of immune myocarditis.Therefore,comprehensive assessment on cardiac function should be conducted before initiating immunotherapy.Cardiac function indicators,electrocardiogram or echocardiography should be regularly monitored during treatment,and glucocorticosteroids or in combination with other treatments should be applied as early as possible when immune myocarditis is suspected.Whether immunotherapy can be restarted should be decided based on the patients'willingness and the results of multidisciplinary consultation evaluation.
维普
万方数据